The global demand for Meningitis Vaccine Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Meningitis vaccine is a vaccine targeted towards teenagers and adults to protect them from meningococcal disease, dangerous inflammation affecting the lining of the brain, and spinal cord. Meningitis causes permanent damage like hearing loss, learning delays, the loss of fingers or toes, brain damage, and even death. This disease can be caused by bacteria, fungi, or a virus. Meningitis vaccine is prescribed for a meningococcal disease affecting kids, adults, military recruits, and people with a damaged or missing spleen and certain immune system disorders. The symptoms of meningitis include nausea, vomiting, altered mental status, and photophobia.
An increase in the occurrences of meningitis in preteens and teens is the main driver for the growth of the meningitis vaccine market. Growing awareness about immunization programs among the global population and the risk of permanent disability in kids affected by meningitis will stimulate market growth. The inclusion of the vaccine in the routine national immunization schedules will propel the market growth. An increase in global healthcare investments and the research and development of new vaccines targeting microbial outbreaks will be a market booster. The main challenges faced by the meningitis vaccine market are stringent government regulations for vaccine approval and low awareness related to the harmful effects of meningitis among the global population.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of meningitis vaccine.
The entire meningitis vaccine market has been sub-categorized into vaccine type, end-user and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Vaccine Type
By Distribution Channel
- Haemophilus Influenza Type B Vaccine
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Meningococcal Vaccine
- Hospital Pharmacies
- Retail Pharmacies
This section covers regional segmentation which accentuates on current and future demand for meningitis vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Meningitis Vaccine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the meningitis vaccine market include GlaxoSmithKline, plc, Pfizer, Inc., Merck & Co., Inc., Sanofi Pasteur SA, Astellas Pharma Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Sciences Corporation, Panacea Biotec. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.